Aadi Bioscience price target lowered to $36 from $45 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Aadi Bioscience to $36 from $45 and keeps a Buy rating on the shares post the Q3 report. The firm reduced long-term forecasts for Fyarro in PEComa.